Advanced search
1 file | 54.56 KB Add to list

2013 Update of the American Society of Clinical Oncology/College of American Pathologists guideline for human epidermal growth factor receptor 2 testing: impact on immunohistochemistry-negative breast cancers

Kathleen Lambein (UGent) , Mieke Van Bockstal (UGent) , Hannelore Denys (UGent) and Louis Libbrecht (UGent)
(2014) JOURNAL OF CLINICAL ONCOLOGY. 32(17). p.1856-1857
Author
Organization
Keywords
Breast Cancer, Guidelines, HER2, Immunohistochemistry, RECOMMENDATIONS

Downloads

  • (...).pdf
    • full text
    • |
    • UGent only
    • |
    • PDF
    • |
    • 54.56 KB

Citation

Please use this url to cite or link to this publication:

MLA
Lambein, Kathleen, Mieke Van Bockstal, Hannelore Denys, et al. “2013 Update of the American Society of Clinical Oncology/College of American Pathologists Guideline for Human Epidermal Growth Factor Receptor 2 Testing: Impact on Immunohistochemistry-negative Breast Cancers.” JOURNAL OF CLINICAL ONCOLOGY 32.17 (2014): 1856–1857. Print.
APA
Lambein, Kathleen, Van Bockstal, M., Denys, H., & Libbrecht, L. (2014). 2013 Update of the American Society of Clinical Oncology/College of American Pathologists guideline for human epidermal growth factor receptor 2 testing: impact on immunohistochemistry-negative breast cancers. JOURNAL OF CLINICAL ONCOLOGY, 32(17), 1856–1857.
Chicago author-date
Lambein, Kathleen, Mieke Van Bockstal, Hannelore Denys, and Louis Libbrecht. 2014. “2013 Update of the American Society of Clinical Oncology/College of American Pathologists Guideline for Human Epidermal Growth Factor Receptor 2 Testing: Impact on Immunohistochemistry-negative Breast Cancers.” Journal of Clinical Oncology 32 (17): 1856–1857.
Chicago author-date (all authors)
Lambein, Kathleen, Mieke Van Bockstal, Hannelore Denys, and Louis Libbrecht. 2014. “2013 Update of the American Society of Clinical Oncology/College of American Pathologists Guideline for Human Epidermal Growth Factor Receptor 2 Testing: Impact on Immunohistochemistry-negative Breast Cancers.” Journal of Clinical Oncology 32 (17): 1856–1857.
Vancouver
1.
Lambein K, Van Bockstal M, Denys H, Libbrecht L. 2013 Update of the American Society of Clinical Oncology/College of American Pathologists guideline for human epidermal growth factor receptor 2 testing: impact on immunohistochemistry-negative breast cancers. JOURNAL OF CLINICAL ONCOLOGY. 2014;32(17):1856–7.
IEEE
[1]
K. Lambein, M. Van Bockstal, H. Denys, and L. Libbrecht, “2013 Update of the American Society of Clinical Oncology/College of American Pathologists guideline for human epidermal growth factor receptor 2 testing: impact on immunohistochemistry-negative breast cancers,” JOURNAL OF CLINICAL ONCOLOGY, vol. 32, no. 17, pp. 1856–1857, 2014.
@article{4412839,
  author       = {{Lambein, Kathleen and Van Bockstal, Mieke and Denys, Hannelore and Libbrecht, Louis}},
  issn         = {{0732-183X}},
  journal      = {{JOURNAL OF CLINICAL ONCOLOGY}},
  keywords     = {{Breast Cancer,Guidelines,HER2,Immunohistochemistry,RECOMMENDATIONS}},
  language     = {{eng}},
  number       = {{17}},
  pages        = {{1856--1857}},
  title        = {{2013 Update of the American Society of Clinical Oncology/College of American Pathologists guideline for human epidermal growth factor receptor 2 testing: impact on immunohistochemistry-negative breast cancers}},
  url          = {{http://dx.doi.org/10.1200/JCO.2013.54.2530}},
  volume       = {{32}},
  year         = {{2014}},
}

Altmetric
View in Altmetric
Web of Science
Times cited: